Takeda Pharmaceutical Co Stock Earnings Per Share
| TKPHF Stock | USD 25.12 0.67 2.74% |
Takeda Pharmaceutical Co fundamentals help investors to digest information that contributes to Takeda Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Takeda Pink Sheet. The fundamental analysis module provides a way to measure Takeda Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Takeda Pharmaceutical pink sheet.
Takeda |
Takeda Pharmaceutical Co Company Earnings Per Share Analysis
Takeda Pharmaceutical's Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current Takeda Pharmaceutical Earnings Per Share | 1.33 X |
Most of Takeda Pharmaceutical's fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Takeda Pharmaceutical Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
| Competition |
According to the company disclosure, Takeda Pharmaceutical Co has an Earnings Per Share of 1.33 times. This is 84.11% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The earnings per share for all United States stocks is 57.37% higher than that of the company.
Takeda Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Takeda Pharmaceutical's direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Takeda Pharmaceutical could also be used in its relative valuation, which is a method of valuing Takeda Pharmaceutical by comparing valuation metrics of similar companies.Takeda Pharmaceutical is currently under evaluation in earnings per share category among its peers.
Takeda Fundamentals
| Return On Equity | 0.0477 | |||
| Return On Asset | 0.0247 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | 0.13 % | |||
| Current Valuation | 75.53 B | |||
| Shares Outstanding | 1.56 B | |||
| Shares Owned By Insiders | 1.20 % | |||
| Shares Owned By Institutions | 41.35 % | |||
| Price To Earning | 27.54 X | |||
| Price To Book | 0.97 X | |||
| Price To Sales | 0.01 X | |||
| Revenue | 3.57 T | |||
| Gross Profit | 2.44 T | |||
| EBITDA | 1.05 T | |||
| Net Income | 230.06 B | |||
| Cash And Equivalents | 645.99 B | |||
| Cash Per Share | 417.82 X | |||
| Total Debt | 4.14 T | |||
| Debt To Equity | 0.81 % | |||
| Current Ratio | 1.18 X | |||
| Book Value Per Share | 3,973 X | |||
| Cash Flow From Operations | 1.12 T | |||
| Earnings Per Share | 1.33 X | |||
| Price To Earnings To Growth | 0.58 X | |||
| Number Of Employees | 47.35 K | |||
| Beta | 0.7 | |||
| Market Capitalization | 50.37 B | |||
| Total Asset | 13.18 T | |||
| Retained Earnings | 1.57 T | |||
| Working Capital | 675.58 B | |||
| Current Asset | 1.48 T | |||
| Current Liabilities | 808.72 B | |||
| Annual Yield | 0.04 % | |||
| Five Year Return | 3.99 % | |||
| Net Asset | 13.18 T | |||
| Last Dividend Paid | 180.0 |
About Takeda Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Takeda Pharmaceutical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Takeda Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Takeda Pharmaceutical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Takeda Pink Sheet
When determining whether Takeda Pharmaceutical is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Takeda Pink Sheet is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Takeda Pharmaceutical Co Stock. Highlighted below are key reports to facilitate an investment decision about Takeda Pharmaceutical Co Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Takeda Pharmaceutical Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.